EMMA
Emmaus Life Sciences, Inc.Company Information
- Company Name
- Emmaus Life Sciences, Inc.
- CIK
- CIK0000822370
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- EMMA: OTC
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- EMMA
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-31
- Last sale
- 2023-12-20
- Shares purchased (TTM)
- 100,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2020-09-30
- Institutional shares owned
- 57,034
- Shares outstanding
- 48,987,189
- Ownership
- 0.12%
Earnings Market Reaction
- Filing date
- 2026-08-14
- Price on filing date
- —
- 1-month reaction
- 423.04%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 3 | 1 | 2 | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 2 | ||||||
| Accounts Receivable Net Current | 1 | 2 | 3 | 3 | 2 | 2 | 3 | 5 | 5 | 3 | 6 | 5 | ||||||
| Inventory Net | 2 | 2 | 2 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Prepaid Expense And Other Assets Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Assets Current | 6 | 6 | 8 | 5 | 5 | 6 | 7 | 9 | 9 | 8 | 12 | 9 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Equity Method Investments | - | - | - | - | - | - | - | - | - | - | - | 18 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | ||||||
| Equity Securities F V N I Noncurrent | 1 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 16 | 19 | 21 | 21 | 23 | 22 | 24 | 27 | 26 | 30 | 35 | 47 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 23 | 24 | 23 | 22 | 19 | 18 | 17 | 19 | 19 | 18 | 17 | 16 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 3 | 2 | 2 | 1 | 1 | 2 | 1 | ||||||
| Other Liabilities Current | 16 | 17 | 18 | 14 | 14 | 16 | 17 | 16 | 14 | 15 | 15 | 14 | ||||||
| Derivative Instruments And Hedges Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Convertible Notes Payable Current | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 16 | 16 | 17 | 16 | - | ||||||
| Liabilities Current | 66 | 71 | 69 | 64 | 62 | 65 | 64 | 64 | 64 | 62 | 62 | 61 | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | ||||||
| Other Liabilities Noncurrent | 13 | 12 | 12 | 12 | 13 | 13 | 13 | 14 | 15 | 17 | 17 | 17 | ||||||
| Liabilities | 83 | 87 | 85 | 80 | 79 | 81 | 80 | 81 | 83 | 83 | 83 | 84 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 226 | 226 | 226 | 226 | 226 | 226 | 226 | 226 | 226 | 226 | 225 | 222 | ||||||
| Receivable From Shareholders Or Affiliates For Issuance Of Capital Stock | -17 | -17 | -17 | -17 | -17 | -17 | -17 | -17 | -17 | -17 | -17 | - | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -3 | -4 | -3 | -0 | 1 | -3 | -3 | -2 | -3 | -2 | -0 | -2 | ||||||
| Retained Earnings Accumulated Deficit | -272 | -273 | -270 | -268 | -266 | -265 | -263 | -261 | -263 | -260 | -256 | -257 | ||||||
| Stockholders Equity | -66 | -68 | -64 | -59 | -56 | -59 | -56 | -54 | -57 | -54 | -48 | -36 | ||||||
| Liabilities And Stockholders Equity | 16 | 19 | 21 | 21 | 23 | 22 | 24 | 27 | 26 | 30 | 35 | 47 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | 250 | ||||||
| Common Stock Shares Issued | 70 | 70 | 70 | 64 | 64 | 64 | 64 | 64 | 64 | 62 | 62 | 54 | ||||||
| Shares Outstanding | 70 | 70 | 70 | 64 | 64 | 64 | 64 | 64 | 64 | 62 | 62 | 54 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialEmmaus Life Sciences, Inc. (EMMA) — SEC Financial Statements & Analysis
Emmaus Life Sciences, Inc. (EMMA) is a pharmaceutical preparations company, incorporated in DE. Emmaus Life Sciences, Inc. trades on OTC as: EMMA. Emmaus Life Sciences, Inc. (EMMA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14. Based on that filing, Emmaus Life Sciences, Inc. carries a market cap of $718.03K, a P/E ratio of -0.10x, a P/B ratio of -0.01x, a P/S ratio of 0.04x, an enterprise value of $15.24M, and an EV/EBITDA multiple of 3.59x. On profitability, it posts a gross margin of 93.76%, an operating margin of 22.78%, a net margin of -39.01%, a Return on Equity (ROE) of 11.75%, and a Return on Assets (ROA) of -36.05%. Per share, it reports EPS of $-0.10, diluted EPS of $-0.06, free cash flow per share of $0.02, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -5.28% year-over-year, net income growth of 28.51% year-over-year, and EPS growth of 16.93% year-over-year. On the balance sheet, it maintains a current ratio of 0.09x, a quick ratio of 0.05x, working capital of $-60.11M, a debt-to-equity ratio of -1.25x, a debt ratio of 5.04, an interest coverage ratio of 0.44x, free cash flow of $1.06M (TTM), and net debt of $14.53M. Figures sourced from SEC EDGAR.
- Market Cap
- $718.03K
- P/E TTM
- -0.10x
- EPS TTM
- $-0.10
- P/B TTM
- -0.01x
- ROE TTM
- 11.75%
- ROA TTM
- -36.05%
- Debt To Equity
- -1.25x
- Free Cash Flow TTM
- $1.06M
- Net Revenue TTM Growth 1Y
- -5.28%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Emmaus Life Sciences, Inc. in?
Emmaus Life Sciences, Inc. (EMMA) operates in the Pharmaceutical Preparations industry.
What exchange does EMMA trade on?
Emmaus Life Sciences, Inc. (EMMA) trades on the OTC.
Where is Emmaus Life Sciences, Inc. incorporated?
Emmaus Life Sciences, Inc. is incorporated in DE.
When was Emmaus Life Sciences, Inc. (EMMA)'s most recent SEC filing?
Emmaus Life Sciences, Inc. (EMMA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-14.
What is EMMA's market cap?
Emmaus Life Sciences, Inc. (EMMA) has a market capitalization of $718.03K as of 2026-06-30.
What is EMMA's EPS (earnings per share)?
Emmaus Life Sciences, Inc. (EMMA)'s trailing twelve month EPS is $-0.10 as of 2026-06-30.
What is EMMA's ROE (return on equity)?
Emmaus Life Sciences, Inc. (EMMA)'s trailing twelve month Return on Equity (ROE) is 11.75% as of 2026-06-30.
What is EMMA's ROA (return on assets)?
Emmaus Life Sciences, Inc. (EMMA)'s trailing twelve month Return on Assets (ROA) is -36.05% as of 2026-06-30.
What is EMMA's EV/EBITDA?
Emmaus Life Sciences, Inc. (EMMA)'s trailing twelve month EV/EBITDA is 3.59x as of 2026-06-30.